单克隆抗体和Ig融合蛋白治疗银屑病的有效性和长期安全性  

Efficacy and safety of monoclonal antibodies and fusion proteins for psoriasis

作　　者：李玲珺[1] 马鹏程[1] 

机构地区：[1]中国医学科学院皮肤病研究所,南京210042

出　　处：《药学与临床研究》2008年第1期32-36,共5页Pharmaceutical and Clinical Research

摘　　要：银屑病是一种慢性T细胞介导的炎性皮肤病,发病机理尚不完全清楚,目前所采用的化学药物的疗效也欠佳,本文综述了近年新研制的单克隆抗体、融合蛋白等生物制剂,它们由于疗效高,副作用少,有可能成为银屑病治疗的更好选择。Psoriasis is a chronic T-lymphocyte mediated inflammatory skin disease, while it＇s exact etiological factor has not been elucidated. Because chemical treatments previously used are unsatisfactory, several biological agents including monoclonal antibodies and fusion proteins may have been developed to be good alternatives for psoriasis due to their high efficacy and relative slight side-effects.

关 键 词：银屑病 生物疗法 单克隆抗体 IG融合蛋白 

分 类 号：R965.3[医药卫生—药理学]